ClinicalTrials.gov
ClinicalTrials.gov Menu

Carbamazepine Treatment of Cocaine Dependence - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000242
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : April 7, 2017
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Medical University of South Carolina

Brief Summary:
The purpose of this study is to compare the efficacy of carbamazepine in treatment of cocaine-dependence in patients with affective disorders.

Condition or disease Intervention/treatment Phase
Cocaine-Related Disorders Substance-Related Disorders Drug: Carbamazepine Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 0 participants
Primary Purpose: Treatment
Official Title: Carbamazepine Treatment of Cocaine Dependence
Actual Study Start Date : October 1, 1992
Actual Primary Completion Date : January 25, 1997
Actual Study Completion Date : January 25, 1997

Resource links provided by the National Library of Medicine

U.S. FDA Resources




Primary Outcome Measures :
  1. Severity addiction
  2. Amount of drug use
  3. Affective stability
  4. Medication compliance


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000242


Locations
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425 742
Sponsors and Collaborators
Medical University of South Carolina
National Institute on Drug Abuse (NIDA)
Investigators
Principal Investigator: Kathleen Brady, Ph.D. Medical University of South Carolina

Publications:
(1) Brady KT et. al. Features of cocaine dependence with concurrent alcohol abuse. Drug and Alcohol Depend. 1995, 39(1):69-71. (2) Brady KT et. al. Personality disorder and assault history in substance-dependent individuals. Am J on Addictions. 1995, 4(4):306-312. (3) Dansky et. al. Use of self-report measures of crime-related posttraumatic stress disorder with substance use disordered patients. Journal of Substance Abuse Treatment. (in press). (4) Sonne an Presentation at CPDD meeting, 1996.

Responsible Party: Medical University of South Carolina
ClinicalTrials.gov Identifier: NCT00000242     History of Changes
Other Study ID Numbers: NIDA-07761-1
R29DA007761 ( U.S. NIH Grant/Contract )
R29-07761-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: April 7, 2017
Last Verified: July 1996

Keywords provided by Medical University of South Carolina:
Cocaine
Substance Abuse

Additional relevant MeSH terms:
Disease
Cocaine-Related Disorders
Substance-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Cocaine
Carbamazepine
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Vasoconstrictor Agents
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Anticonvulsants
Antimanic Agents
Tranquilizing Agents
Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers